OS Therapies Files 8-K on Financials
Ticker: OSTX · Form: 8-K · Filed: Aug 15, 2024 · CIK: 1795091
| Field | Detail |
|---|---|
| Company | Os Therapies Inc (OSTX) |
| Form Type | 8-K |
| Filed Date | Aug 15, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
OS Therapies dropped an 8-K on Aug 15th detailing their financials. Check it for the latest.
AI Summary
OS Therapies Inc. filed an 8-K on August 15, 2024, reporting on its Results of Operations and Financial Condition. The filing provides information regarding the company's financial statements and exhibits, with the principal executive offices located in Grasonville, Maryland.
Why It Matters
This 8-K filing provides crucial updates on OS Therapies Inc.'s financial condition and operational results, which are important for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting financial information and does not indicate any immediate or significant risks.
Key Players & Entities
- OS Therapies Inc. (company) — Registrant
- August 15, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Grasonville, Maryland (location) — Address of Principal Executive Offices
- 410-297-7793 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing for OS Therapies Inc.?
The primary purpose of this 8-K filing is to report on the Results of Operations and Financial Condition of OS Therapies Inc., including its Financial Statements and Exhibits.
On what date was the earliest event reported in this filing?
The earliest event reported in this filing was on August 15, 2024.
Where are the principal executive offices of OS Therapies Inc. located?
The principal executive offices of OS Therapies Inc. are located at 115 Pullman Crossing Road, Suite 103, Grasonville, Maryland 21638.
In which U.S. state is OS Therapies Inc. incorporated?
OS Therapies Inc. is incorporated in Delaware.
What is the telephone number provided for OS Therapies Inc.?
The telephone number provided for OS Therapies Inc. is (410) 297-7793.
Filing Stats: 516 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2024-08-15 16:05:33
Key Financial Figures
- $0.001 — ch Registered Common Stock, par value $0.001 per share OSTX NYSE American Indi
Filing Documents
- ea0211542-8k_ostherap.htm (8-K) — 27KB
- ea021154201ex99-1_ostherap.htm (EX-99.1) — 21KB
- 0001213900-24-069622.txt ( ) — 226KB
- ostx-20240815.xsd (EX-101.SCH) — 3KB
- ostx-20240815_lab.xml (EX-101.LAB) — 33KB
- ostx-20240815_pre.xml (EX-101.PRE) — 22KB
- ea0211542-8k_ostherap_htm.xml (XML) — 4KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On August 15, 2024, OS Therapies Incorporated, an ADC and immunotherapy research and clinical-stage biopharmaceutical company, issued a press release announcing its financial results for the second quarter ended June 30, 2024. A copy of the press release is furnished with this report as Exhibit 99.1. Such information, including the Exhibit attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release issued by OS Therapies Incorporated on August 15, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1 Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OS THERAPIES INCORPORATED Dated: August 15, 2024 By: /s/ Paul A. Romness Name: Paul A. Romness, MPH Title: President and Chief Executive Officer 2